NTX 1107
Alternative Names: NTX-1107Latest Information Update: 16 Mar 2022
At a glance
- Originator Nectin Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Nectin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 10 Mar 2022 Preclinical trials in Haematological malignancies in USA (Parenteral) (Nectin Therapeutics pipeline, March 2022)
- 10 Mar 2022 Preclinical trials in Solid tumours in USA (Parenteral) (Nectin Therapeutics pipeline, March 2022)
- 10 Mar 2022 Nectin Therapeutics plans to initiate IND enabling studies for Solid tumours in second half of 2022 (Nectin Therapeutics pipeline, March 2022)